초록 ▼

This invention relates to apparatus and methods of delivering various compositions including medicaments to a variety of targets. The invention includes a dose administrator (1) which may be used for intranasal delivery of compositions or medicaments, such as live virus vaccines, to both humans and

This invention relates to apparatus and methods of delivering various compositions including medicaments to a variety of targets. The invention includes a dose administrator (1) which may be used for intranasal delivery of compositions or medicaments, such as live virus vaccines, to both humans and animals. An axial collapse prevention element (2) to prevent excessive axial deflection of the dose administrator (1) or a dose-location coordinate indicator (3) to facilitate the delivery of a dose to the desired target location may be coupled to the dose administrator (1). An intranasal probe (4) having a force dissemination contact surface (7) may be responsive to a first end of the dose administrator (1). The dose may be delivered from a conformable dose sequestration element (10) through an aperture which penetrates the dose delivery aperture element (5) and the dose may be caused to stream by coupling a stream delivery element (6) to the dose delivery aperture element (5). The force application element (12) which acts upon the dose may be separated from the dose by a fluid dose propellent (13). While the invention may be used for numerous applications, it specifically addresses the difficulties of delivering cold-adapted live equine influenza viruses intranasally to equids.

대표청구항 ▼

We claim: 1. An equine intranasal dose delivery device, comprising: a flexible tubular dose administrator having a length disposed between a first end and a second end and having an external surface configured to insert substantially the entirety of said length within a nasal passage of an equid an

We claim: 1. An equine intranasal dose delivery device, comprising: a flexible tubular dose administrator having a length disposed between a first end and a second end and having an external surface configured to insert substantially the entirety of said length within a nasal passage of an equid animal; b. at least one dose delivery aperture which allows fluidic communication between the interior and the exterior of said flexible dose administrator, said at least one dose delivery aperture having a location proximate said first end of said flexible tubular dose administrator; and c. a stream delivery element coupled within said at least one dose delivery aperture, said stream delivery element having a structure configured to deliver an equine dose in a dose diluent substantially as a stream to avoid delivery of said equine dose as discrete particles to a target within said nasal passage of said equid animal. 2. An equine intranasal dose delivery device as described in claim 1, wherein said flexible tubular dose administrator has a length of between about 75 millimeters and about 180 millimeters. 3. An equine intranasal dose delivery device as described in claim 2, wherein said flexible tubular dose administrator has an external diameter of between about 2 millimeters and about 7 millimeters. 4. An equine intranasal dose delivery device as described in claim 3, wherein said flexible tubular dose administrator has a wall thickness of between about 0.3 millimeters and about 1.6 millimeters. 5. An equine intranasal dose delivery device as described in claim 4, wherein said tubular configuration has an internal diameter of between about 1.4 and about 4.0 millimeters. 6. An equine intranasal dose delivery device as described in claim 1, wherein said flexible tubular dose administrator has a length of between about 130 millimeters and about 160 millimeters. 7. An equine intranasal dose delivery device as described in claim 6, wherein said flexible tubular dose administrator has an external diameter of between about 6 millimeters and about 7 millimeters. 8. An equine intranasal dose delivery device as described in claim 7, wherein said flexible tubular dose administrator has a wall thickness of about 0.35 millimeters. 9. An equine intranasal dose delivery device as described in claim 8, wherein said tubular configuration has an internal diameter of about 1.8 millimeters. 10. An equine intranasal dose delivery device as described in claim 1, wherein said flexible tubular dose administrator has a length of about 155 millimeters. 11. An equine intranasal dose delivery device as described in claim 10, wherein said flexible tubular dose administrator has an external diameter of between about 2 millimeters and about 3 millimeters. 12. An equine intranasal dose delivery device as described in claim 11, wherein said flexible tubular dose administrator has a wall thickness of about 1.5 millimeter. 13. An equine intranasal dose delivery device as described in claim 12, wherein said tubular configuration has an internal diameter of about 3.3 millimeters. 14. An equine intranasal dose delivery device as described in claim 1, wherein said at least one dose delivery aperture comprises a plurality of dose delivery apertures. 15. An equine intranasal dose delivery device as described in claim 1, wherein said at least one dose delivery aperture comprises at least two dose delivery apertures. 16. An equine intranasal dose delivery device as described in claim 1, wherein said at least one dose delivery aperture comprises at least three dose delivery apertures. 17. An equine intranasal dose delivery device as described in claim 1, wherein said at least one dose delivery aperture comprises at least four dose delivery apertures. 18. An equine intranasal dose delivery device as described in claim 1, wherein said flexible tubular dose administrator and said at least one dose delivery aperture comprise a single piece flexible tubular dose administrator having said at least one dose delivery aperture proximate to said first end. 19. An equine intranasal dose delivery device as described in claim 1, further comprising an intranasal probe coupled to said flexible tubular dose administrator, wherein said at least one dose delivery aperture passes through said intranasal probe to provide communication between the interior and the exterior of said flexible tubular dose administrator. 20. An equine intranasal dose delivery device as described in claim 1, wherein said coupler and said flexible tubular dose administrator comprise a single piece flexible tubular dose administrator having said second end configured to engage a propellant source. 21. An equine intranasal dose delivery device as described in claim 20, wherein said coupler further comprises a luer configured to engage a syringe. 22. An equine intranasal dose delivery device as described in claim 21, wherein said luer further comprises a luer lock to fix position of said syringe relative to said luer. 23. An equine intranasal dose delivery device as described in claim 1, wherein said equine dose has a location in the interior of said flexible tubular dose administrator. 24. An equine intranasal dose delivery device as described in claim 1, wherein the interior of said flexible tubular dose administrator sequesters said equine dose. 25. An equine intranasal dose delivery device as described in claim 1, said equine dose comprises a material selected from the group consisting of: a substance, a composition, a therapeutic composition, a prophylactic composition, a drug, a protein, a nucleic acid, an immunogen, an immunogen which elicits an immune response, a live virus, a reassortant live virus, a cold-adapted live virus, an attenuated live virus, an equine cold-adapted live influenza virus which replicates in embryonated chicken eggs within a temperature range from about 26° C. to about 30° C., an equine influenza cold-adapted live virus which does not form plaques in tissue culture cells at a temperature above about 37° C., an equine influenza cold-adapted live virus which does not form plaques in tissue culture cells at a temperature above about 39° C., a equine cold-adapted live virus having a phenotype wherein protein synthesis is inhibited above about 39° C., an equine cold-adapted live virus having a dominant interference phenotype, an equine influenza cold-adapted live virus derived from strain A/equine/Kentucky/1/91 (H3N8), EIV-P821 (identified by accession No. ATCC VR 2625), EIV-P824 (identified by accession No. ATCC VR 2624), MSV+5 (identified by accession No. 2627), any progeny of any of said equine influenza viruses identified by such accession Nos., any EIV having the identifying characteristics of said ATCC VR strains, or an equine influenza cold adapted live virus having about 105 TCID50 to about 108 TCID50 units. 26. An equine intranasal dose delivery device as described in claim 1, wherein said tubular dose administrator has sufficient flexure to position said at least one aperture at a location within the nasal passage of an equid beyond the nasal diverticulum.